1. South Korea Stocks

  2. •

    Health technology

  3. •

    Biotechnology
Naturalendo Tech Co., Ltd.

Naturalendo Tech Co., Ltd.

KKRX:168330
2,065.00
KRW
+25.00
(+1.23%)
-94.69EPS
66.94BMarket Cap
Naturalendo Tech Co., Ltd.
KRX:168330
(Korea Stock Exchange)

Recent

price

2,065.00

P/E

ratio

- -

div

yld

- -

ROIC.AI

2012
2013
2014
2015
2016
2017
2018
2019
2020
2021
2022
2023
2024
2025
TTM
KRW
1,415.43
1,385.25
6,460.19
2,303.28
339.81
474.41
440.93
321.35
649.37
546.89
444.09
593.62
704.66
703.73
686.98
Revenue per Share
287.5
317.5
1,081
-803
-683
-455
-963
-655
-82
-189
-321
-138
-123
-102
-73
Basic EPS, GAAP
135.9
265.61
-1,349.05
-490.02
-990.42
-417.07
-563.41
-315.43
-143.22
-192.6
-183.06
-185.08
-77.64
-185.21
-146.77
Free Cash Flow per Basic Share
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
Dividend per Share
471.8
2,676.51
3,706.06
2,615.37
2,451.27
2,375.13
1,617.16
1,018.93
856.01
1,407.9
1,122.88
984.53
861.44
759.41
762.83
Book Value per Share
426.1
2,612.17
3,622.19
2,562.98
2,399.8
2,039.52
1,538.61
994.59
833.91
1,394.03
1,109.93
971.58
847.23
744.09
747.64
Tangible Book Value per Share
15
61
19
19
19
19
20
20
20
27
31
32
32
32
32
Basic Weighted Avg Shares
21,633
84,118
124,067
44,506
6,556
9,239
8,928
6,580
13,247
14,696
13,951
18,790
22,263
22,227
21,690
Sales/Revenue/Turnover
23.66
28.65
20.86
-24.47
-143.25
-58.35
-152.18
-169.13
-2.38
-40.23
-60.48
-21.72
-16.93
-14.82
-12.17
Operating Margin (%)
53
94
771
1,073
1,346
1,432
2,598
1,959
1,420
1,669
1,735
1,545
1,235
824
832
Depreciation Expense
4,394
19,280
20,761
-15,516
-13,177
-8,861
-19,500
-13,413
-1,673
-5,079
-10,084
-4,368
-3,886
-3,222
-2,305
Net Income, GAAP
16.2
20.83
20.53
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
Effective Tax Rate (%)
20.31
22.92
16.73
-34.86
-200.99
-95.91
-218.4
-203.82
-12.63
-34.56
-72.28
-23.25
-17.46
-14.49
-10.63
Profit Margin (%)
6,633
37,365
22,255
1,981
42,486
36,581
662
13,418
-10,668
16,246
10,640
6,426
2,789
5,139
5,184
Working Capital
1,059
- -
1,160
1,650
31,418
24,975
948
25,480
3,470
155
251
1,417
1,349
6,347
6,398
LT Debt
8,951
50,780
71,648
50,463
47,297
54,719
36,487
20,483
15,822
45,368
36,580
30,943
26,866
23,246
23,177
Total Equity
- -
56.83
31.16
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
Return on Invested Capital (%)
- -
63.38
33.6
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
Return on Capital (%)
- -
64.56
33.91
-25.41
-26.96
-18.67
-48.3
-49.68
-8.71
-16.6
-25.5
-13.13
-13.34
-12.59
-9.13
Return on Common Equity (%)

Capital Structure

KRW

•

in mil. unless spec.
Sep'25
Dec'25
Mar'26
ST Debt
3,821
2,960
2,335
LT Borrowings
5,000
6,300
6,300
LT Finance Leases
38
47
98
Preferred Equity and Hybrid Capital
- -
- -
- -
Shares Outstanding
32
32
32
Market Capitalization
85,564
97,877
66,935

Working Capital

KRW

•

in mil. unless spec.
Sep'25
Dec'25
Mar'26
Total Current Assets
12,040
10,718
10,657
Cash, Cash Equivalents & STI
3,304
1,291
1,338
Accounts Receivable, Net
1,197
2,355
2,460
Inventories
6,455
6,383
6,104
Total Current Liabilities
7,236
5,579
5,473
Payables & Accruals
- -
- -
- -
ST Debt
3,821
2,960
2,335
Deferred Revenue
- -
- -
- -

Growth Rates

KRW

•

in mil. unless spec.

(avg. rate of change)

10 years
5 years
1 year
Total Equity
3.48%
25.07%
-13.47%
Free Cash Flow
15.71%
34.09%
138.46%
Net Income, GAAP
17.08%
43.47%
-17.1%
Sales/Revenue/Turnover
8.62%
11.77%
-0.16%
Total Cash Common Dividend
- -
- -
- -

Quarterly Revenue

KRW

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
5,233
5,737
6,462
4,831
22,263
2025
6,238
5,052
5,754
5,182
22,227
2026
5,702
- -
- -
- -
- -

Quarterly Earnings Per Share

KRW

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
-37
-29
-31
-26.87
-123
2025
-26
-31.18
-20.48
-24.77
-102
2026
3.42
- -
- -
- -
- -

Quarterly Dividends Per Share

KRW

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
- -
- -
- -
- -
- -
2025
- -
- -
- -
- -
- -
2026
- -
- -
- -
- -
- -
Similar Companies
Moderna, Inc. (NASDAQ:MRNA)
Iovance Biotherapeutics, Inc. (NASDAQ:IOVA)
Amgen Inc. (NASDAQ:AMGN)
Recursion Pharmaceuticals, Inc. (NASDAQ:RXRX)
Novavax, Inc. (NASDAQ:NVAX)
Kodiak Sciences Inc (NASDAQ:KOD)
Business
Naturalendo Tech Co., Ltd. is a South Korea-based biotechnology and healthcare company that specializes in the research, development, and manufacturing of natural bioactive ingredients, health functional foods, and dermatological cosmetics. Founded in 2001 and headquartered in Seongnam-si, Gyeonggi-do, South Korea, the company operates under the majority ownership of Suheung Co., Ltd. and trades on the KOSDAQ market. The company operates across two principal business divisions: Health Functional Foods and Cosmetics. Its product and service offerings include EstroG-100, a proprietary botanical complex extract composed of Cynanchum wilfordii, Phlomis umbrosa, and Angelica gigas Nakai formulated for the relief of female menopausal symptoms; specialized functional ingredients and dietary formulations, including HabaNova for weight management, YGF 251 for adolescent growth support, and NET 2401 for sleep-wake cycle regulation; NEEDIN, an inner-beauty and digestive enzyme product line; NEEDLY, a consumer skincare brand featuring daily toner pads, clarifying ampoules, cleansing oils, and blemish treatments; and EndoSkin, a proprietary portfolio of dissolvable microneedle patches utilizing transdermal drug delivery system technology developed through its biotechnology subsidiary, Endoderma Co., Ltd. Naturalendo Tech supplies both direct-to-consumer finished goods and business-to-business raw materials to pharmaceutical companies, supplement manufacturers, and beauty retailers across domestic and international markets, including South Korea, North America, Europe, and the Asia-Pacific region. In recent developments, the company has driven a strategic revenue shift toward its high-growth cosmetics business, establishing the NEEDLY brand as a primary sales contributor while expanding global retail distribution into international channels such as Costco Canada and regional e-commerce platforms. Concurrently, following operational integration under Suheung Co., Ltd., Naturalendo Tech has strengthened international licensing and distribution partnerships to broaden regulatory approvals and market penetration for its core EstroG-100 ingredient across European, Middle Eastern, and Asian markets.